Business Description
PaxMedica Inc
NAICS : 541714
SIC : 2833
ISIN : US70424C2035
Share Class Description:
MEX:PXMD: Ordinary SharesDescription
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.03 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 1.33 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.6 | |||||
3-Year EPS without NRI Growth Rate | 5.7 | |||||
3-Year FCF Growth Rate | -17.5 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 4.88 | |||||
14-Day RSI | 7.3 | |||||
12-1 Month Momentum % | -96.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.4 | |||||
Quick Ratio | 2.4 | |||||
Cash Ratio | 1.35 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -157.9 | |||||
Shareholder Yield % | -389.72 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -1026.94 | |||||
ROA % | -418.1 | |||||
ROIC % | -1491.03 | |||||
ROC (Joel Greenblatt) % | -4025.07 | |||||
ROCE % | -809.16 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.37 | |||||
Price-to-Tangible-Book | 1.36 | |||||
EV-to-EBIT | -0.14 | |||||
EV-to-EBITDA | -0.14 | |||||
EV-to-FCF | -0.2 | |||||
Price-to-Net-Current-Asset-Value | 1.36 | |||||
Earnings Yield (Greenblatt) % | -744.46 | |||||
FCF Yield % | -555.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PaxMedica Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | |||
EPS (TTM) (MXN) | -316.593 | ||
Beta | 0 | ||
Volatility % | 113.72 | ||
14-Day RSI | 7.3 | ||
14-Day ATR (MXN) | 0.00005 | ||
20-Day SMA (MXN) | 15.69 | ||
12-1 Month Momentum % | -96.45 | ||
52-Week Range (MXN) | 15.69 - 442 | ||
Shares Outstanding (Mil) | 7.78 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
PaxMedica Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
PaxMedica Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
PaxMedica Inc Frequently Asked Questions
What is PaxMedica Inc(MEX:PXMD)'s stock price today?
The current price of MEX:PXMD is MXN15.69. The 52 week high of MEX:PXMD is MXN442.00 and 52 week low is MXN15.69.
When is next earnings date of PaxMedica Inc(MEX:PXMD)?
The next earnings date of PaxMedica Inc(MEX:PXMD) is 2024-08-09 Est..
Does PaxMedica Inc(MEX:PXMD) pay dividends? If so, how much?
PaxMedica Inc(MEX:PXMD) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |